Liposomal encapsulation enhances the antitumour efficacy of the vascular disrupting agent ZD6126 in murine B16.F10 melanoma
| Autor: | Marcel H.A.M. Fens, F R Westwood, Raymond M. Schiffelers, K J Hill, Anderson J. Ryan, David C. Blakey, J Issa, Gert Storm, Susan Ashton |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2008 |
| Předmět: |
liposomes
Cancer Research Pathology medicine.medical_specialty Umbilical Veins Endothelium endothelium Vascular Disrupting Agent ZD6126 Melanoma Experimental Antineoplastic Agents Pharmacology Biomedische technologie en medicijnen chemistry.chemical_compound Mice Organophosphorus Compounds In vivo Medical technology Medicine Animals Humans Tissue Distribution ZD6126 Liposome Neovascularization Pathologic business.industry Macrophages Farmacie(FARM) Endothelial Cells drug targeting Immunohistochemistry Endothelial stem cell medicine.anatomical_structure Oncology Targeted drug delivery chemistry vascular disrupting agents business Drug carrier Translational Therapeutics |
| Zdroj: | British Journal of Cancer, 99, 1256. Nature Publishing Group British Journal of Cancer |
| ISSN: | 1532-1827 0007-0920 |
| Popis: | Vascular disrupting agents (VDAs) are able to affect selectively tumour endothelial cell morphology resulting in vessel occlusion and widespread tumour cell necrosis. However, single-agent antitumour activity of VDAs is typically limited, as tumour regrowth occurs rapidly following drug treatment. To improve the therapeutic effectiveness of VDAs, we investigated liposomal targeting using ZD6126 as a model VDA. ZD6126 is a phosphate-prodrug of the tubulin-binding vascular disrupting agent ZD6126 phenol. ZD6126 was encapsulated into long circulating PEG-liposomes for passive targeting and PEG-liposomes conjugated with peptide ligands containing the RGD-motif for active targeting to alpha(v)-integrins on tumour endothelial cells. ZD6126 could be stably encapsulated, and liposomes displayed minimal leakage in vitro ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|